ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	46,156	$	35,495
Restricted cash	1,501		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	47,657	$	36,996

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.

(in thousands)	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	46,156	$	35,495
Restricted cash	1,501		1,501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	47,657	$	36,996

Property and Equipment

Property and equipment consisted of the following:

(in thousands, except useful lives)	Estimated Useful Lives				December 31, 2021		December 31, 2020
Leasehold improvements			5	Years	$	—	$	167
Lab equipment			5	Years	530		530
Manufacturing equipment			5	Years	138		138
Computer and office equipment	3	to	5	Years	841		834
Software			3	Years	94		94
Total					1,603		1,763
Less: accumulated depreciation					(1,591)		(1,574)
Property and equipment, net					$	12	$	189

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

	December 31, 2021		December 31, 2020
Accrued payroll	$	320	$	1,071
Accrued patient treatment costs	2,086		899
Accrued clinical research costs	479		1,562
Accrued manufacturing costs	328		41
Accrued professional services	305		279
Accrued other	331		313
Total accrued expenses and other current liabilities	$	3,849	$	4,165

Earnings Per Share, Potentially Dilutive Securities

The following outstanding shares of common stock equivalents were excluded from the computations of diluted earnings per share (if in a net income position) of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.

	December 31, 2021	December 31, 2020
Anti-dilutive common stock equivalents:	Number of Shares
Redeemable convertible series 1 preferred stock	4,520,000	4,520,000
Warrants to purchase common stock	5,750,000	11,616,080
Private placement option	—	9,675,000
Options to purchase common stock	2,140,618	1,510,968
Unvested shares of restricted stock units	137,504	129,861
Total anti-dilutive common stock equivalents	12,548,122	27,451,909